Spyre Therapeutics (SYRE) Research & Development (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Research & Development came in at $60.4 million in Q1 2026, up 45.14% YoY from $41.6 million in Q1 2025, and up 35.34% on a QoQ basis from $44.6 million in Q4 2025.
Spyre Therapeutics (SYRE) Research & Development (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Research & Development data on file, last reported at $60.4 million in Q1 2026.
- Quarterly Research & Development rose 45.14% year-over-year to $60.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.4 million (up 12.36% YoY) and the FY2025 annual result came in at $171.7 million, up 5.44% from the prior year.
- Research & Development advanced to $60.4 million in Q1 2026, from $44.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $60.4 million in Q1 2026 to a low of $12.0 million in Q3 2022.
- A 5-year average of $31.9 million and a median of $33.7 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development fell 19.36% — and 2024, when it surged 153.54%.
- Tracing SYRE's Research & Development over 5 years: stood at $14.3 million in 2022, then soared by 136.35% to $33.7 million in 2023, then soared by 49.88% to $50.5 million in 2024, then decreased by 11.58% to $44.6 million in 2025, then jumped by 35.34% to $60.4 million in 2026.
- The last three Research & Development figures came in at $60.4 million (Q1 2026), $44.6 million (Q4 2025), and $45.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 65.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.50 Mn |
| Mar 31, 2026 | 60.41 Mn |
| Dec 31, 2025 | 44.64 Mn |
| Sep 30, 2025 | 45.25 Mn |
| Jun 30, 2025 | 40.15 Mn |
| Mar 31, 2025 | 41.62 Mn |
| Dec 31, 2024 | 50.48 Mn |
| Sep 30, 2024 | 44.74 Mn |
| Jun 30, 2024 | 32.64 Mn |
| Mar 31, 2024 | 34.93 Mn |
| Dec 31, 2023 | 33.68 Mn |
| Sep 30, 2023 | 24.66 Mn |
| Jun 30, 2023 | 17.39 Mn |
| Mar 31, 2023 | 13.78 Mn |
| Dec 31, 2022 | 14.25 Mn |
| Sep 30, 2022 | 11.98 Mn |
| Jun 30, 2022 | 15.37 Mn |
| Mar 31, 2022 | 16.98 Mn |
| Dec 31, 2021 | 16.78 Mn |
| Sep 30, 2021 | 14.85 Mn |